tradingkey.logo

BRIEF-Regeneron's DB-OTO Results Show Hearing Improvements In Children With Profound Genetic Hearing Loss

ReutersFeb 24, 2025 8:07 PM

- Regeneron Pharmaceuticals Inc REGN.O:

  • REGENERON: DB-OTO RESULTS SHOW CLINICALLY MEANINGFUL HEARING IMPROVEMENTS IN NEARLY ALL CHILDREN WITH PROFOUND GENETIC HEARING LOSS IN CHORD TRIAL

  • REGENERON: 10 OF 11 CHILDREN WITH AT LEAST ONE POST-TREATMENT ASSESSMENT SHOWED NOTABLE IMPROVEMENTS IN HEARING IN PHASE 1/2 CHORD TRIAL

  • REGENERON: 72-WEEK RESULTS FOR DB-OTO SHOWS SPEECH AND DEVELOPMENT PROGRESS IN FIRST CHILD DOSED AT 10 MONTHS OF AGE

Source text: [ID:]

Further company coverage: REGN.O

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI